2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI

Published

Journal Article

© 2018 Science China Press East Asians are the most populous race in the world and their health status is an important global issue. Compared with Caucasian populations, East Asian patients have a different benefit/risk ratio when using antithrombotic treatment. Despite this observation, treatment strategies in East Asian patients are mostly based on the American and European guidelines. Despite a lower platelet inhibitory response to clopidogrel, East Asian patients show a similar or even a lower rate of ischemic event occurrence and higher bleeding risk compared with Caucasian patients. For potent P2Y 12 inhibitors (ticagrelor and prasugrel), East Asian patients have shown less favorable net clinical benefits compared with Caucasian patients, which may be related to differences in pharmacokinetic/pharmacodynamic profiles and therapeutic zone of antiplatelet effect. This updated consensus mainly focuses on state-of-the-art and current controversies in the East Asian population. In addition, when East Asian patients are administered potent P2Y 12 receptor inhibitors, the strategies and ongoing trials to overcome the related hurdles are discussed.

Full Text

Duke Authors

Cited Authors

  • Huo, Y; Jeong, YH; Gong, Y; Wang, D; He, B; Chen, J; Fu, G; Chen, Y; Li, J; Li, Y; Goto, S; Tantry, US; Gurbel, PA; Ahn, JH; Kim, HS; Ho Jeong, M; Han, Y; Smith, SC; Ge, J

Published Date

  • February 15, 2019

Published In

Volume / Issue

  • 64 / 3

Start / End Page

  • 166 - 179

Electronic International Standard Serial Number (EISSN)

  • 2095-9281

International Standard Serial Number (ISSN)

  • 2095-9273

Digital Object Identifier (DOI)

  • 10.1016/j.scib.2018.12.020

Citation Source

  • Scopus